🇺🇸 FDA
Pipeline program

Placebo for BMS-936558, OPDIVO 10 mg/mL concentrate for solution for infusion.

CA209-577

Phase 3 small_molecule active

Quick answer

Placebo for BMS-936558, OPDIVO 10 mg/mL concentrate for solution for infusion. for Subjects with resected adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancer is a Phase 3 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).

Program details

Company
Bristol-Myers Squibb / Pfizer EEIG
Indication
Subjects with resected adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials